APRES
APRES
Angiotensin-converting enzyme inhibition Post REvascularization Study. A trial assessing ramipril’s effect, if any, on the incidence of cardiac events after revascularisation in patients with angina and LVEF of 30% to 50%.Primary endpoint Composite of cardiac death, nonfatal acute myocardial infarction, development of clinical heart failure or recurrent angina.
Conclusions Long-term ramipril after invasive revascularisation significantly reduces the composite end point.